Trust the Success of Your Schizophrenia Clinical Trials to Worldwide

According to the World Health Organization (WHO), approximately 23 million people around the world have schizophrenia.[i] For many, the distorted thinking and intrusive psychotic experiences – including hallucinations and delusions – caused by the disorder can be debilitating. And, although medications have been developed to treat schizophrenia, they do not work for all patients, and there is evidence that some forms of schizophrenia appear to be treatment resistant.

For researchers working on therapies targeted at schizophrenia, Worldwide Clinical Trials is your natural partner. For more than 30 years, we have been supporting clinical trials focusing on CNS and psychiatric disorder research. Our experts have authored more than hundreds of peer-reviewed articles and several textbooks regarding the field of CNS pharmaceutical research. Additionally, Worldwide has been involved in numerous CNS clinical trials, involving thousands of patients, related to psychiatric disorders.

Researchers working with Worldwide know that we provide a stable team of project professionals who already have experience in psychiatric research and trial management. You’re not working with people who are starting from scratch. All that experience ensures insightful feedback on development plans, detailed and expert feasibility analyses, and the skills to deliver a project on time and on budget.

[i] http://www.who.int/news-room/fact-sheets/detail/mental-disorders